Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

43.92 -0.14 (-0.31%)
Streaming Delayed Price Updated: 1:52 PM EST, Feb 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,460,330
Open 44.19
Bid (Size) 43.92 (13)
Ask (Size) 43.93 (29)
Prev. Close 44.06
Today's Range 43.73 - 44.30
52wk Range 41.45 - 56.32
Shares Outstanding 5,606,688,356
Dividend Yield 3.55%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
5 Stocks That Moved the Market in January
These stocks illustrate the most important trends in the stock market right now. 
Via The Motley Fool
The 3 Most Undervalued Growth Stocks for Your February Buy List
These undervalued growth stocks have the value and projected growth that investors seek when researching their next investment decisions. 
Via InvestorPlace

Performance

YTD
-14.31%
-14.31%
1 Month
-13.74%
-13.74%
3 Month
-6.72%
-6.72%
6 Month
-11.39%
-11.39%
1 Year
-17.45%
-17.45%

More News

Read More
Is Gilead Sciences a Good Stock to Buy Now?
Via The Motley Fool
Five Best And Worst Performing Healthcare Stocks In January 2023
Via Talk Markets
Barron's Top Weekend Stock Picks: Apple, Disney, Pfizer And Tesla's Price Cuts Are Leading To Growth
Via Benzinga
Pfizer's Sales Could Sink 33% in 2023. Here's Why to Buy the Stock Anyway.
Via The Motley Fool
Pfizer (PFE) Q4 2022 Earnings Call Transcript
Via The Motley Fool
Top 5 Health Care Stocks That May Rally
Via Benzinga
Biosimilars Market 2023 Industry Size, Share, Growth and Analysis by Demand, Opportunity, Key Players, Regional Development and Forecast 2029
Via SBWire
Topics Intellectual Property
Exposures Intellectual Property
Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?
Via The Motley Fool
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
Via MarketBeat
Topics ETFs
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
Via Investor's Business Daily
Got $1,000? 3 Cheap Stocks To Buy Right Now
Via The Motley Fool
This Low-Risk ETF Can Turn $39,000 Into $1 Million in 25 Years
Via The Motley Fool
Novavax Shares Jumped in January While Others Slipped
Via MarketBeat
Exposures COVID-19 Product Safety
AMD To Rally Over 26%? Here Are 10 Other Analyst Forecasts For Wednesday
Via Benzinga
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Via MarketBeat
S&P 500 Jumps 1.5%, Market Volatility Decreases
Via Benzinga
1 Reason to Buy Novavax in 2023 and 2 Reasons to Sell
Via The Motley Fool
Dow Surges Over 200 Points; Pfizer Issues Weak Forecast
Via Benzinga
AbbVie's Two-Decade Humira Monopoly Ends With Amgen's 55% Discounted Knockoff
Via Investor's Business Daily
Waiting for Powell: As Fed Meeting Starts, Investors Parse Mixed Q4 Earnings and Consider What's Next for Rates
Via Benzinga
Sony Scales Back PlayStation VR2 Output, Sam Bankman-Fried Attempted To Regain Control Of FTX, White House Plans To End COVID-19 Emergency: Today's Top Stories
Via Benzinga
Why BioNTech And Moderna Shares Are Falling After Pfizer News
Via Benzinga
Most Important Week Of Earnings Season Is Here — Will S&P 500 Companies Continue Beating Wall Street Estimates?
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.